Titan Pharmaceuticals, Inc. common stock (TTNP) Forecasted to Earn Q2 2018 Earnings of ($0.17) Per Share

Titan Pharmaceuticals, Inc. common stock (NASDAQ:TTNP) – Analysts at Zacks Investment Research issued their Q2 2018 earnings estimates for shares of Titan Pharmaceuticals, Inc. common stock in a research note issued to investors on Tuesday, May 22nd. Zacks Investment Research analyst J. Vandermosten forecasts that the specialty pharmaceutical company will post earnings per share of ($0.17) for the quarter. Zacks Investment Research also issued estimates for Titan Pharmaceuticals, Inc. common stock’s Q3 2018 earnings at ($0.13) EPS, Q4 2018 earnings at ($0.12) EPS, FY2018 earnings at ($0.53) EPS and FY2020 earnings at $0.12 EPS.

Titan Pharmaceuticals, Inc. common stock (NASDAQ:TTNP) last posted its quarterly earnings results on Wednesday, May 16th. The specialty pharmaceutical company reported ($0.12) EPS for the quarter, beating the consensus estimate of ($0.13) by $0.01. The firm had revenue of $1.06 million during the quarter, compared to analysts’ expectations of $0.07 million. Titan Pharmaceuticals, Inc. common stock had a negative return on equity of 480.80% and a negative net margin of 1,122.44%.



A number of other brokerages have also recently issued reports on TTNP. Roth Capital set a $2.00 target price on Titan Pharmaceuticals, Inc. common stock and gave the stock a “hold” rating in a report on Tuesday, April 3rd. ValuEngine raised Titan Pharmaceuticals, Inc. common stock from a “strong sell” rating to a “sell” rating in a report on Wednesday, May 2nd.

Shares of Titan Pharmaceuticals, Inc. common stock opened at $0.83 on Friday, according to Marketbeat Ratings. Titan Pharmaceuticals, Inc. common stock has a 1 year low of $0.60 and a 1 year high of $2.85. The company has a quick ratio of 1.75, a current ratio of 1.75 and a debt-to-equity ratio of -4.06. The company has a market capitalization of $16.58 million, a PE ratio of -1.19 and a beta of 1.41.

A hedge fund recently raised its stake in Titan Pharmaceuticals, Inc. common stock stock. Renaissance Technologies LLC increased its holdings in shares of Titan Pharmaceuticals, Inc. common stock (NASDAQ:TTNP) by 25.4% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 552,200 shares of the specialty pharmaceutical company’s stock after buying an additional 111,800 shares during the quarter. Renaissance Technologies LLC owned 2.60% of Titan Pharmaceuticals, Inc. common stock worth $732,000 as of its most recent SEC filing. 7.30% of the stock is currently owned by institutional investors and hedge funds.

About Titan Pharmaceuticals, Inc. common stock

Titan Pharmaceuticals, Inc, a pharmaceutical company, develops proprietary therapeutics for the treatment of serious medical disorders in the United States. It develops products based on ProNeura, a proprietary long-term drug delivery technology that focuses primarily on treatments for chronic diseases.

Earnings History and Estimates for Titan Pharmaceuticals, Inc. common stock (NASDAQ:TTNP)

Receive News & Ratings for Titan Pharmaceuticals Inc. common stock Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Titan Pharmaceuticals Inc. common stock and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply